By rray, 12 July, 2024 Exclude Patient Type Detail Header No Detail Type Text Detail Text Offer oral antimuscarinics darifenacin fesoterodine oxybutynin solifenacin tolterodine trospium or 3 adrenoceptor agonists mirabegron vibegron SR A Transdermal oxybutynin patch Oxytrol males only Rx and Oxytrol for Women OTC may be offered R C Choose tx based on side effect profile in the context of shared decision making CP nbsp nbsp Antimuscarinics common dry mouth constipation voiding dysfunction incomplete emptying retention blurred vision rare palpitations tachycardia and QT prolongation w Discuss potential risk for dementia and cognitive impairment w pts taking or prescribed antimuscarinics CP Don t use antimuscarinics if narrow angle glaucoma unless approved by pt s ophthalmologist use w extreme caution if impaired gastric emptying or urinary retention hx CP if PVR 250 300 mL use w caution If obstructive voiding sx appear monitor PVR Assess tx for efficacy and onset of side effects w in 4 8wk of tx initiation EO nbsp nbsp If intolerable side effects or inadequate improvement May offer a different medication in the same class or a medication from a different class CP For pts on antimus Patient Type Detail Header (Long) Pharmacotherapy